Sanofi said FDA issued a complete response letter to an NDA for Zynquista sotagliflozin as an adjunct to insulin for adults with Type I diabetes. The news sent shares of partner Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) down $1.74 (22%) to $6.20 on Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,